Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +50.00% and +0.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?